Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib + MTX + Chemoimmunotherapy in DLBCL with CNS Involvement
NCT07812493Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Complete Remission Rate at 18 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pirtobrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07812493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812493.